Codanin-1 mutations engineered in human erythroid cells demonstrate role of CDAN1 in terminal erythroid maturation.


Journal

Experimental hematology
ISSN: 1873-2399
Titre abrégé: Exp Hematol
Pays: Netherlands
ID NLM: 0402313

Informations de publication

Date de publication:
11 2020
Historique:
received: 29 06 2020
revised: 14 09 2020
accepted: 15 09 2020
pubmed: 20 10 2020
medline: 16 1 2021
entrez: 19 10 2020
Statut: ppublish

Résumé

The generation of a functional erythrocyte from a committed progenitor requires significant changes in gene expression during hemoglobin accumulation, rapid cell division, and nuclear condensation. Congenital dyserythropoietic anemia type I (CDA-I) is an autosomal recessive disease that presents with erythroid hyperplasia in the bone marrow. Erythroblasts in patients with CDA-I are frequently binucleate and have chromatin bridging and defective chromatin condensation. CDA-1 is most commonly caused by mutations in Codanin-1 (CDAN1). The function of CDAN1 is poorly understood but it is thought to regulate histone incorporation into nascent DNA during cellular replication. The study of CDA-1 has been limited by the lack of in vitro models that recapitulate key features of the disease, and most studies on CDAN1 function have been done in nonerythroid cells. To model CDA-I we generated HUDEP2 mutant lines with deletion or mutation of R1042 of CDAN1, mirroring mutations found in CDA-1 patients. CDAN1 mutant cell lines had decreased viability and increased intercellular bridges and binucleate cells. Further, they had alterations in histone acetylation associated with prematurely elevated erythroid gene expression, including gamma globin. Together, these data imply a specific functional role for CDAN1, specifically R1042 on exon 24, in the regulation of DNA replication and organization during erythroid maturation. Most importantly, generation of models with specific patient mutations, such as R1042, will provide further mechanistic insights into CDA-I pathology.

Identifiants

pubmed: 33075436
pii: S0301-472X(20)30594-4
doi: 10.1016/j.exphem.2020.09.201
pmc: PMC7741183
mid: NIHMS1643365
pii:
doi:

Substances chimiques

CDAN1 protein, human 0
Chromatin 0
Glycoproteins 0
Nuclear Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-38.e6

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK104920
Pays : United States

Informations de copyright

Copyright © 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Références

Br J Haematol. 2019 May;185(3):436-449
pubmed: 30836435
Epigenetics Chromatin. 2020 Mar 16;13(1):16
pubmed: 32178723
Blood. 2006 Jan 1;107(1):334-40
pubmed: 16141353
Eur J Haematol. 2017 Jan;98(1):13-18
pubmed: 27206021
Methods. 2017 Jan 1;112:68-74
pubmed: 27582124
Curr Protoc Mol Biol. 2015 Jul 01;111:28.6.1-28.6.11
pubmed: 26131851
Mol Cell. 2011 Mar 4;41(5):502-14
pubmed: 21362547
Front Physiol. 2014 Jan 28;5:3
pubmed: 24478716
Am J Hum Genet. 2002 Dec;71(6):1467-74
pubmed: 12434312
Cell Cycle. 2018;17(12):1413-1424
pubmed: 29954236
Exp Hematol. 2019 Jun;74:19-24.e4
pubmed: 31004744
Blood. 1996 Mar 1;87(5):1763-70
pubmed: 8634422
Blood Adv. 2020 Apr 14;4(7):1464-1477
pubmed: 32282884
Cell Rep. 2016 Oct 25;17(5):1453-1461
pubmed: 27783956
Haematologica. 2009 May;94(5):629-37
pubmed: 19336738
Blood. 2011 Jun 23;117(25):6928-38
pubmed: 21364188
J Clin Pathol. 1986 Aug;39(8):881-90
pubmed: 2427549
Br J Haematol. 2005 Nov;131(4):431-46
pubmed: 16281933
Blood. 2011 Nov 10;118(19):5071-9
pubmed: 21885599
Cell Rep. 2016 Aug 2;16(5):1470-1484
pubmed: 27452463
Blood. 2014 May 29;123(22):3466-77
pubmed: 24637361
Dev Cell. 2012 Mar 13;22(3):610-24
pubmed: 22421046
Nat Methods. 2015 Oct;12(10):982-8
pubmed: 26322839
EMBO J. 2012 Apr 18;31(8):2013-23
pubmed: 22407294
Blood. 2013 Apr 18;121(16):3246-53
pubmed: 23422750
Trends Cell Biol. 2011 Jul;21(7):409-15
pubmed: 21592797
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Pediatr Res. 1982 Dec;16(12):1016-21
pubmed: 6185913
Eur J Haematol. 2017 Oct;99(4):366-371
pubmed: 28755517

Auteurs

Zachary C Murphy (ZC)

Center for Pediatric Biomedical Research, Department of Pediatrics, University of Rochester, Rochester, NY.

Michael R Getman (MR)

Center for Pediatric Biomedical Research, Department of Pediatrics, University of Rochester, Rochester, NY.

Jaquelyn A Myers (JA)

Center for Pediatric Biomedical Research, Department of Pediatrics, University of Rochester, Rochester, NY.

Kimberly N Burgos Villar (KN)

Aab Cardiovascular Research Institute, University of Rochester, Rochester, NY.

Emily Leshen (E)

Center for Pediatric Biomedical Research, Department of Pediatrics, University of Rochester, Rochester, NY.

Ryo Kurita (R)

Research and Development Department, Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.

Yukio Nakamura (Y)

Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Ibaraki, Japan.

Laurie A Steiner (LA)

Center for Pediatric Biomedical Research, Department of Pediatrics, University of Rochester, Rochester, NY. Electronic address: laurie_steiner@urmc.rochester.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH